Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

EGFR Monoclonal Antibody Therapy in NSCLC: A Focus on Erbitux
Author
Howard (Jack) West, MD

Most of the discussion with about inhibiting the EGFR axis in lung cancer has focused on the orally available tyrosine kinase inhibitors (TKIs) that work inside the cells. However, another way to inhibit the cells is by giving an IV "monoclonal antibody" which is a protein that attaches to the outside of the cell at the EGFR target and can block activity. A figure of the two approaches is shown here, with the antibody circled in red:

EGFR INhibition (Click to enlarge)

Cetuximab, or erbitux, is by far the most studied in cancer. This agent, you may recall, is the one that Martha Stewart was indicted over:

Martha Steward image

It's now approved in colon cancer and also in head and neck cancer, but it's been the subject of much less research in lung cancer than the EGFR TKIs like Iressa and Tarceva.

I mentioned in my last post that I recommend against treating patients with standard chemotherapy and EGFR TKIs at the same time because I am concerned that the activity of these two approaches may interfere with each other. I would not generalize that conclusion to EGFR monoclonal antibodies like Erbitux, which is still not very well studied and just doesn't have enough data either way to say if or how it might be used in lung cancer.

One rather small European study called the LUCAS trial enrolled 86 patients with advanced NSCLC to receive cisplatin and navelbine alone or with weekly erbitux and showed hints of a benefit, which is about the best you could do in such a paltry trial:

LUCAS trial

As is often the case, the preliminary presentation of the trial (abstract here) looked more promising than a later version with more follow-up (abstract here). The results in the figure above reflect the more recent results, which are fairly encouraging, with modest improvements in response rate and survival in the folks who received chemo with erbitux. In terms of side effects, erbitux consistently causes the EGFR rash, which can be quite profound, but not much diarrhea, and otherwise it increases fatigue and the decrease in blood counts compared with chemo alone. Patients can also get a hypersensitivity reaction when it is being infused, an allergic-like reaction that can rarely be severe. It is generally given on a weekly basis, starting with a loading doses that is higher than the ones that follow.

Over the past few years, a few other rather small trials have combined erbitux with other chemo regimens like carbo and paclitaxel (abstract here) and carboplatin and gemcitabine (abstract here), and they have looked modestly promising, but we have yet to see any trial large enough to give a meaningful answer to whether erbitux adds significantly to a chemo doublet alone. The most important trial that can address this is called the FLEX trial, which is a larger version of the LUCAS trial and gives cisplatin and navelbine with or without weekly erbitux, is being conducted outside of the US and has enrolled all of the planned patients, over 1100. There was a safety review (abstract here) that showed no unexpected side effects that would lead to the trial closing. The results of this trial are expected in 2007.

One trial that does have results available is by the Southwest Oncology Group, or SWOG. Karen Kelly, now at the University of Kansas, presented SWOG 0342, a trial in which a total of 225 eligible patients with advanced NSCLC received first-line carbo/paclitaxel, and half of them received weekly erbitux with that. All of the patients received maintenance erbitux weekly until progression or for up to one year after those four initial cycles of chemo with or without erbitux. The trial design is shown here:

SWOG 0342

The trial was fairly encouraging, with the median progression-free survival of about four months, and the arm that received erbitux with chemo showing a little longer overall survival compared to chemo alone followed by maintenance erbitux(10 vs. 9 months). However, the expert who provided commentary after that presentation at our major annual meeting (ASCO) noted that for neither arm were the results particularly impressive compared to what we expect from chemo alone.

The current trial that SWOG is doing will combine carboplatin and paclitaxel along with erbitux AND avastin. Known as SWOG 0536, it will enroll 90 patients who are considered candidates for avastin (no squamous tumors, no brain metastases) and have previously untreated advanced NSCLC. After chemo, patients continue on maintenance avastin every 3 weeks and erbitux weekly. The design is shown here:

SWOG 0536 schema

The participating sites are available by hitting the "Where is this Study Open?" button at the bottom of the page linked here. This trial is designed first to text the safety, specifically assessing the risk of bleeding on this treatment plan, and the second goal is to evaluate survival with this four-drug combination. However, many people have expressed concern that this combination could also have major financial side effects, since both cetuximab and avastin can run in the tens of thousands of dollars per year.

Taking these results together, there really is at this time no clear role that erbitux has in lung cancer, at least not yet. It has shown some hints of promise, but whether this approach adds to what we have with EGFR TKIs is still questionable. Fortunately, the FLEX trial and other studies should provide more information soon.

I'll do another post summarizing the small amount of work that has looked at erbitux as a single agent in lung cancer.

Next Previous link

Previous PostNext Post

Related Content

Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments. To watch the complete playlist click here.
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.

Forum Discussions

Hi and welcome to Grace.  Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

JOIN THE CONVERSATION
 Hi arm2966, Welcome to…
By JanineT GRACE … on
Joanne indwelling catheters
By arm2966 on
Hi and welcome to Grace. …
By JanineT GRACE … on
Hi Amber, Welcome to Grace. …
By JanineT GRACE … on